Ricerca di nuovi marcatori diagnostici/prognostici ERA DEGLI "OMICS"

- ✓GENOMICA
  - ✓ESPRESSIONE GENICA:
    - trascriptoma
    - miRNOMA
    - metilomica
  - ✓PROTEOMICA
  - ✓METABOLOMICA

BIOMARCATORI NON INVASIVI
La Biopsia Liquida

TUMORE

sangue



DNA libero circolante
miRNA circolanti
Cellule Tumorali Circolanti

miR e ACC

NCBI Resources How To Sign in to NCBI

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed | miRNA adrenal tumors | Search

Create RSS Create alert Advanced Help

Article types
Clinical Trial
Review
Customize ...

Text availability
Abstract
Free full text
Full text

Format: Summary Sort by: Most Recent Per page: 20 Send to

Filters: Manage Filters

Search results

Items: 1 to 20 of 69

<< First < Prev Page 1 of 4 Next > Last >>

Next-generation sequencing reveals microRNA markers of adrenocortical **tumors** malignancy.

1. Koperski Ł, Kotlarek M, Świerniak MA, Kolanowska M, Kubiak A, Górnicka B, Jażdżewski K, Wójcicka

ortical **tumors**?

Find related data

Database: Select

Find items

Search details

```
("micrornas"[MeSH Terms] OR
"micrornas"[All Fields] OR
"mirna"[All Fields]) AND
("adrenal gland neoplasms"[MeSH
Terms] OR ("adrenal"[All Fields]
AND "gland"[All Fields] AND
```

Search See more...

ARTICLE IN PRESS

Molecular and Cellular Endocrinology xxx (2016) 1–8

Contents lists available at ScienceDirect

Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

ELSEVIER

The role of microRNAs in the pathophysiology of adrenal tumors

Nunki Hassan [a, b], Jing Ting Zhao [a, b], Stan B. Sidhu [a, b, c, *]

[a] Cancer Genetics Laboratory, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, Australia
[b] Sydney Medical School Northern, Royal North Shore Hospital, University of Sydney, Australia
[c] University of Sydney Endocrine Surgery Unit, Royal North Shore Hospital, Sydney, St Leonards, Sydney, NSW, Australia

Oncotarget, Advance Publications 2017

Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy

Łukasz Koperski[1], Marta Kotlarek[2], Michał Świerniak[2,3], Monika Kolanowska[2,3], Anna Kubiak[2,3], Barbara Górnicka[1], Krystian Jażdżewski[2,3] and Anna Wójcicka[2,3]

[1]Department of Pathology, Medical University of Warsaw, Warsaw, Poland
[2]Laboratory of Human Cancer Genetics, Centre of New Technologies, CENT, University of Warsaw, Warsaw, Poland
[3]Genomic Medicine, Medical University of Warsaw, Warsaw, Poland

miRNA in ACC



26 ACC
10 ACA
21 NOR





Patterson et al, Cancer 2010

Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients

Endocrine-Related Cancer
(2013) **20**, 579–594

O Chabre[1,2,3,4], R Libé[5,6,7], G Assie[5,6,7], O Barreau[5,6,7], J Bertherat[5,6,7], X Bertagna[5,6,7], J-J Feige[1,3,4] and N Cherradi[1,3,4]



9 naACC
14 aACC
14 ACA
19 NOR



Valore diagnostico miRNA siero

New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer

Francesca Salvianti[1,*], Letizia Canu[1,*], Giada Poli[1], Roberta Armignacco[1], Cristian Scatena[2], Giulia Cantini[1], Alessandra Di Franco[1], Stefania Gelmini[1], Tonino Ercolino[1], Mario Pazzagli[1], Gabriella Nesi[3], Massimo Mannelli[1], Pamela Pinzani[1,*] and Michaela Luconi[1,*]

	Mean (SD)	N Patients	%
Age at surgery (years)	45.3(16.2)	27	100
Sex			
Male		11	41
Female		18	59
Secretion		17	63
Cortisol		10	37
Androgens		8	30
DHEAS		2	7
Progestins		1	4
Tumor Diameter (cm)	8.8(4.9)	27	100
Ki67 (%)	26.8(24.7)	25	92.6
WEISS	6.5(1.9)	24	88.9
Stage			
1		6	22
2		12	44
3		4	15
4		5	19
Metastases	Lung, liver, bone, pancreas, contralateral adrenal	5	18.5
Surgery		27	100
Surgery Resection	R0	18	67
	R2	5	22
	nd	3	11
Mitotane therapy		21	78
Other Chemotherapies (Etoposide-Doxorubicin-Cisplatin, taxol)		10	37
Radiotherapy		0	0
Follow-up from surgery (months)	17.6(17.3)	27	100
Survival		21	78



miR483-5p predice OS e RFS



The range of the standard curve obtained on miR from H295R was 0.00523-5.23-pg miRNA. The quantity of miR483 and miR483-5p was calculated by interpolating the Cq values of qPCR on the standard curve and expressed as total miRNA equivalents. The results were normalized for the volume of plasma and expressed as ng equivalents/ml plasma

Taqman Small RNA assays (Life Technologies, USA): hsa-miR483 and hsa-miR483-5p on plasma samples





miR483 correla negativamente con MTT levels





miR483-5p e MTT

Studio pilota osservazionale:

HP: livelli plasmatici miR483-5p correlano inversamente con livelli

- ✓ Campioni di plasma (500ul)
- ✓ Criteri di inclusione: pz ACC stadio 4
  trattamento MTT
- ✓ Prima e dopo inizio MTT
- ✓ Valori di MTT negli stessi prelievi

CONCLUSIONI

- Nuovi markers diagnostici/prognostici a livello tumorale
- Nuovi markers diagnostici/prognostici non invasivi per diagnosi preoperatoria e follow-up

validare su casistiche estese

Club surrene & ENSAT

combinazione nuovi markers

in associazione con diagnostica classica

Cellule Tumorali Circolanti in ACC

J Clin Endocrinol Metab 98: 3731–3738, 2013

ORIGINAL ARTICLE

Endocrine Research

Detection of Circulating Tumor Cells in Patients With Adrenocortical Carcinoma: A Monocentric Preliminary Study

Pamela Pinzani,* Cristian Scatena,* Francesca Salvianti, Elisa Corsini, Letizia Canu, Giada Poli, Milena Paglierani, Valentina Piccini, Mario Pazzagli, Gabriella Nesi, Massimo Mannelli, and Michaela Luconi

Clinical Biochemistry (P.P., F.S., M.Paz.) and Endocrinology (E.C., L.C., G.P., V.P., M.M., M.L.) Units, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50139, Italy; Division of Pathological Anatomy (C.S., M.Pag., G.N.), Department of Surgery and Translational Medicine, University of Florence, Florence 50139, Italy; and Istituto Toscano Tumori (M.M.), Florence 50139, Italy

miR483-5p predice OS e FS